Low estradiol-to-testosterone ratio is associated with oligo-anovulatory cycles and atherogenic lipidic pattern in women with polycystic ovary syndrome

References

• Cohen PG. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt a major factor in the genesis of morbid obesity. Med Hypotheses 1999;52:49–51.
   PubMed Web of Science ®Google Scholar
• Schneider G, Kirschner MA, Berkowitz R, Ertel NH. Increased estrogen production in obese men. J Clin Endocrinol Metab 1979;48:633–638.
   PubMed Web of Science ®Google Scholar
• Fejes I, Koloszár S, Závaczki Z, Daru J, Szöllösi J, Pál A. Effect of body weight on testosterone/estradiol ratio in oligozoospermic patients. Arch Androl 2006;52:97–102.
   PubMed Web of Science ®Google Scholar
• Pont A, Goldman ES, Sugar AM, Siiteri PK, Stevens DA. Ketoconazole-induced increase in estradiol–testosterone ratio. Probable explanation for gynecomastia. Arch Intern Med 1985;145:1429–1431.
   PubMed Web of Science ®Google Scholar
• Rochira V, Balestrieri A, Madeo B, Spaggiari A, Carani C. Congenital estrogen deficiency in men: a new syndrome with different phenotypes; clinical and therapeutic implications in men. Mol Cell Endocrinol 2002;93:19–28.
   Google Scholar
• Tanaka K, Sakai H, Hashizume M, Hirohata T. Serum testosterone:estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. Cancer Res 2000;60:5106–5110.
   PubMed Web of Science ®Google Scholar
• Kendler M, Blendinger C, Haas E. Elevated serum estradiol/testosterone ratio in men with primary varicose compared with a healthy control group angiology. Angiology 2009;60:283–289.
   Google Scholar
• Horng SG, Wang TH, Wang HS. Estradiol-to-testosterone ratio is associated with response to metformin treatment in women with clomiphene citrate-resistant polycystic ovary syndrome (PCOS). Chang Gung Med J 2008;31:477–483.
   Google Scholar
• Rice S, Pellatt L, Ramanathan K, Whitehead SA, Mason HD. Metformin inhibits aromatase via an ERK (extracellular signal-regulated kinase) – mediated pathway. Endocrinology 2009;150:4794–4801.
   PubMed Web of Science ®Google Scholar
• Jakimiuk AJ, Weitsman SR, Brzechffa PR, Magoffin DA. Aromatase mRNA expression in individual follicles from polycystic ovaries. Mol Hum Reprod 1998;4:1–8.
   PubMed Web of Science ®Google Scholar
• Schipper I, Rommerts FF, Ten Hacken PM, Fauser BC. Low levels of follicle-stimulating hormone receptor-activation inhibitors in serum and follicular fluid from normal controls and anovulatory patients with or without polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:1325–1331.
   Google Scholar
• Agarwal SK, Judd HL, Magoffin DA. A mechanism for the suppression of estrogen production in polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:3686–3691.
   PubMed Web of Science ®Google Scholar
• Jakimiuk AJ, Weitsman SR, Magoffin DA. 5α-Reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1999;84:2414–2418.
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, et al Task force on the phenotype of the polycystic ovary syndrome of the Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456–488.
   PubMed Web of Science ®Google Scholar
• Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–1447.
   PubMed Web of Science ®Google Scholar
• The IDF consensus worldwide definition of the metabolic syndrome. Available from http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf. Accessed 07 June 2005.
   Google Scholar
• The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–47.
   PubMed Web of Science ®Google Scholar
• Carmina E, Orio F, Palomba S, Longo RA, Lombardi G, Lobo RA. Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters. Fertil Steril 2005;84:413–419.
   PubMed Web of Science ®Google Scholar
• Christensen JT, Boldsen J, Westergaard JG. Ovarian volume in gynecologically healthy women using no contraception, or using IUD or oral contraception. Acta Obstet Gynecol Scand 1997;76:784–789.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and bcell function from fasting plasma glucose and insulin in man. Diabetologia 1985;28:412–419.
   PubMed Web of Science ®Google Scholar
• Matsuda M, De Fronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 2001;24:460–464.
   Google Scholar
• Ghosh D, Griswold J, Erman M, Pangborn W. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature 2009;457:219–223.
   PubMed Web of Science ®Google Scholar
• Bukulmez O, Arici A. Luteal phase defect: myth or reality. Obstet Gynecol Clin North Am 2004;31:727–744.
   PubMed Web of Science ®Google Scholar
• Phillips GB, Jing T, Heymsfield SB. Relationships in men of sex hormones, adiposity, and risk factors for myocardial infarction. Metabolism 2003;52:784–790.
   PubMed Web of Science ®Google Scholar
• Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999;20:535–582.
   PubMed Web of Science ®Google Scholar
• Pugeat M, Crave JC, Elmidani M, Nicolas MH, Garoscio-Cholet M, Lejeune H, Déchaud H, Tourniaire J. Pathophysiology of sex hormone binding globulin (SHBG): relation to insulin. J Steroid Biochem Mol Biol 1991;40:841–849.
   PubMed Web of Science ®Google Scholar
• Puder JJ, Muller B, Keller U. Letter re: The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance. J Clin Endocrinol Metab 2005;90:4419–4420.
   Google Scholar
• Galluzzo A, Amato MC, Giordano C. Insulin resistance and polycystic ovary syndrome. Nutr Metab Cardiovasc Dis 2008;18:511–518.
   PubMed Web of Science ®Google Scholar
• Elisaf MS, Bairaktari ET, Nicolaides C, Kakaidi B, Tzallas CS, Katsaraki A, Pavlidis NA. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 2001;37:1510–1513.
   PubMed Web of Science ®Google Scholar
• Wojtacki J, Kruszewski W, Sliwinska M, et al Effect of non steroidal aromatase inhibitors (AI) on serum lipid profile in patients with breast cancer. Preliminary report. Eur J Cancer 2000;36:S5 (Abstr 146).
   Google Scholar
• Nicolaides C, Elisaf M, Bairaktari E, et al The effect of aromatase inhibitor letrozole on lipid parameters in postmenopausal women with advanced breast cancer. A preliminary report. Ann Oncol 2000;1:12 (Abstr 380).
   Google Scholar
• Harper-Wynne C, Ross P, Sacks N, et al A pilot prevention study of aromatase inhibitor letrozole: effects on breast cell proliferation and bone/lipid indices in healthy postmenopausal women. Breast Cancer Res Treat 2001;69:225.
   Google Scholar
• Rochira V, Balestrieri A, Madeo B, Spaggiari A, Carani C. Congenital estrogen deficiency in men: a new syndrome with different phenotypes; clinical and therapeutic implications in men. Mol Cell Endocrinol 2002;31:19–28.
   Google Scholar
• Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985;61:946–951.
   PubMed Web of Science ®Google Scholar
• Mahabeer S, Naidoo C, Norman RJ, Jialal I, Reddi K, Joubert SM. Metabolic profiles and lipoprotein lipid concentrations in non-obese and obese patients with polycystic ovarian disease. Horm Metab Res 1990;22:537–540.
   Google Scholar
• Guzick DS, Talbott EO, Sutton-Tyrrell K, Herzog HC, Kuller LH, Wolfson SK Jr. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case–control study. Am J Obstet Gynecol 1996;174:1224–1229; discussion: 1229–1232.
   PubMed Web of Science ®Google Scholar
• Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Kuller L. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995;15:821–826.
   PubMed Web of Science ®Google Scholar
• Banaszewska B, Pawelczyk L, Spaczynski RZ, Dziura J, Duleba AJ. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J Clin Endocrinol Metab 2007;92:456–461.
   PubMed Web of Science ®Google Scholar
• Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J Clin Endocrinol Metab 2009;94:103–108.
   PubMed Web of Science ®Google Scholar
• Izquierdo D, Foyouzi N, Kwintkiewicz J, Duleba AJ. Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis. Fertil Steril 2004;82:1193–1197.
   PubMed Web of Science ®Google Scholar